Philip Lienau

Medicine · Health Sciences

24h-index2.3kcitations116works4.22yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer-related Molecular Pathways(37), Advanced Breast Cancer Therapies(31), Cancer Mechanisms and Therapy(31), Microtubule and mitosis dynamics(14), DNA Repair Mechanisms(8)

Publications116 total

Abstract 6978: Discovery and characterization of BAY-805, a potent and selective DUB inhibitor of ubiquitin specific peptidase USP21
Cancer Research·2025
Discovery and Characterization of BAY-184: A New Potent and Selective Acylsulfonamide-Benzofuran <i>In Vivo</i>-Active KAT6AB Inhibitor
Journal of Medicinal Chemistry·2024· 8 citedOpen Access
Discovery of BAY 2666605, a Molecular Glue for PDE3A and SLFN12
ACS Medicinal Chemistry Letters·2024· 5 citedOpen Access
Discovery of YAP1/TAZ pathway inhibitors through phenotypic screening with potent anti-tumor activity via blockade of Rho-GTPase signaling
Cell chemical biology·2024· 9 cited
Abstract 4584: Novel YAP1/TAZ pathway inhibitors identified through phenotypic screening with potent anti-tumor activity via blockade of GGTase-I and Rho-GTPase signaling
Cancer Research·2024
Velcrin molecular glues induce apoptosis in glioblastomas with high <i>PDE3A</i> and <i>SLFN12</i> expression
Neuro-Oncology Advances·2024· 3 citedOpen Access
EXTH-38. VELCRIN MOLECULAR GLUES INDUCE CELL DEATH IN GLIOBLASTOMAS WITH HIGH <i>PDE3A</i> AND <i>SLFN12</i> EXPRESSION
Neuro-Oncology·2023Open Access
Novel YAP1/TAZ pathway inhibitors identified through phenotypic screening with potent anti-tumor activity via blockade of GGTase-I / Rho-GTPase signaling
2023Open Access
Supplementary Tables from The Novel ATR Inhibitor BAY 1895344 Is Efficacious as Monotherapy and Combined with DNA Damage–Inducing or Repair–Compromising Therapies in Preclinical Cancer Models
2023Open Access
Supplementary Figures from The Novel ATR Inhibitor BAY 1895344 Is Efficacious as Monotherapy and Combined with DNA Damage–Inducing or Repair–Compromising Therapies in Preclinical Cancer Models
2023Open Access
Supplementary Table 3 from BAY 1000394, a Novel Cyclin-Dependent Kinase Inhibitor, with Potent Antitumor Activity in Mono- and in Combination Treatment upon Oral Application
2023Open Access
Supplementary Materials and Methods; Supplementary Tables 1-6; and Supplementary Figure Legends from Novel Mps1 Kinase Inhibitors with Potent Antitumor Activity
2023Open Access
Suppl. Figure 3 from Novel Mps1 Kinase Inhibitors with Potent Antitumor Activity
2023Open Access
Supplementary Tables from The Novel ATR Inhibitor BAY 1895344 Is Efficacious as Monotherapy and Combined with DNA Damage–Inducing or Repair–Compromising Therapies in Preclinical Cancer Models
2023Open Access
Data from BAY 1000394, a Novel Cyclin-Dependent Kinase Inhibitor, with Potent Antitumor Activity in Mono- and in Combination Treatment upon Oral Application
2023Open Access
Suppl. Figure 2 from Novel Mps1 Kinase Inhibitors with Potent Antitumor Activity
2023Open Access
Data from The Novel ATR Inhibitor BAY 1895344 Is Efficacious as Monotherapy and Combined with DNA Damage–Inducing or Repair–Compromising Therapies in Preclinical Cancer Models
2023Open Access
Data from BAY 1000394, a Novel Cyclin-Dependent Kinase Inhibitor, with Potent Antitumor Activity in Mono- and in Combination Treatment upon Oral Application
2023Open Access
Supplementary Figure Legend from BAY 1000394, a Novel Cyclin-Dependent Kinase Inhibitor, with Potent Antitumor Activity in Mono- and in Combination Treatment upon Oral Application
2023Open Access
Supplementary Figure 1 from BAY 1000394, a Novel Cyclin-Dependent Kinase Inhibitor, with Potent Antitumor Activity in Mono- and in Combination Treatment upon Oral Application
2023Open Access
page 1 of 6Next →

Frequent Co-authors

Gerhard Siemeister(21), Dominik Mumberg(21), Antje M. Wengner(18), Franz von Nussbaum(17), Ulrich Lücking(15), Karl Ziegelbauer(14), Knut Eis(12), Michael Brands(11), Hans Briem(11), Ulf Bömer(10), Andreas Reichel(10), Benjamin Bader(9), Martina Schäfer(9), Matthew Meyerson(9), Christoph A. Schatz(8), Arne Scholz(8), Dirk Kosemund(7), Charlotte Kopitz(7), Stefan Gradl(7), Stuart Ince(6)